摄碘阳性的分化型甲状腺癌淋巴结转移灶<sup>131</sup>I疗效分析

梅晓然; 冯方; 王辉; 韦智晓

doi:10.19401/j.cnki.1007-3639.2022.11.007

您当前的位置：

首页 >

文章列表页 >

摄碘阳性的分化型甲状腺癌淋巴结转移灶¹³¹I疗效分析

论著 | 更新时间：2025-12-31

- 摄碘阳性的分化型甲状腺癌淋巴结转移灶¹³¹I疗效分析
- Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after ¹³¹I treatment
- 中国癌症杂志 2022年32卷第11期页码：1091-1097
- 作者机构：
  
  1. 广西医科大学第一附属医院核医学科，广西南宁 530021
  2. 上海交通大学医学院附属新华医院核医学科，上海 200092
- 作者简介：
  
  [ "梅晓然（ORCID: 0000-0003-1289-7778），硕士。" ]
  韦智晓（ORCID: 0000-0003-3466-2902），硕士，教授、主任医师。
- 基金信息：
  
  国家自然科学基金面上项目(81974269)
- DOI：10.19401/j.cnki.1007-3639.2022.11.007
  中图分类号： R736.1
- 收稿：2022-05-31，
  
  修回：2022-08-17，
  
  纸质出版：2022-11-30
- 稿件说明：
移动端阅览
梅晓然, 冯方, 王辉, 等. 摄碘阳性的分化型甲状腺癌淋巴结转移灶¹³¹I疗效分析[J]. 中国癌症杂志, 2022,32(11):1091-1097.

Xiaoran MEI, Fang FENG, Hui WANG, et al. Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after ¹³¹I treatment[J]. China Oncology, 2022, 32(11): 1091-1097.
梅晓然, 冯方, 王辉, 等. 摄碘阳性的分化型甲状腺癌淋巴结转移灶¹³¹I疗效分析[J]. 中国癌症杂志, 2022,32(11):1091-1097. DOI： 10.19401/j.cnki.1007-3639.2022.11.007.

Xiaoran MEI, Fang FENG, Hui WANG, et al. Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after ¹³¹I treatment[J]. China Oncology, 2022, 32(11): 1091-1097. DOI： 10.19401/j.cnki.1007-3639.2022.11.007.

摘要

背景与目的：

淋巴结转移（lymph node metastasis，LNM）是分化型甲状腺癌（differentiated thyroid carcinoma，DTC）最常见的转移，而

131

I对LNM的疗效存在争议，本研究旨在明确

131

I对摄碘良好的LNM的疗效及影响因素。

方法：

纳入2015年1月—2019年6月在上海交通大学医学院附属新华医院接受

131

I治疗的90例DTC患者，共计161个摄碘阳性的转移淋巴结。分析患者的临床及影像学资料，应用SPSS 24.0软件进行统计分析。计量资料按照正态分布，进行独立样本

检验比较，计数资料的比较采用

检验，用logistic回归进行多因素分析，建立多个定量指标与结局为

131

I治疗无效的关系间的受试者工作特征（receiver operating characteristic，ROC）曲线，并得到最佳诊断阈值。

结果：

161个摄碘阳性的转移淋巴结中，有效组为71个（44.10%），无效组为90个（55.90%）。单因素分析提示，两组患者在年龄、性别、病理学类型、原发病灶数量、原发病灶位置、有无远处转移及血清甲状腺球蛋白（thyroglobulin，Tg）水平等方面差异均有统计学意义（

0.05）。多变量logistic回归分析显示，病理学类型（OR = 11.827，95% CI：1.128 ~ 123.978，

= 0.039）、有无远处转移（OR = 0.220，95% CI：0.093 ~ 0.522，

= 0.001）和原发病灶数量（OR = 0.421，95% CI：0.212 ~ 0.837，

= 0.014）与治疗后的转归密切相关。

结论：

原发病灶多灶、病理学类型为甲状腺乳头状癌（papillary thyroid carcinoma，PTC）、远处转移、血清Tg高于43.51 ng/mL及转移淋巴结的最大径大于16.8 mm是摄碘阳性淋巴结

131

I治疗无效的危险因素，建议对此类患者加大治疗剂量或尽早选择手术切除。

Abstract

Background and purpose:

Lymph node metastasis (LNM) is the most common metastasis of differentiated thyroid cancer (DTC)

and the efficacy of

131

I on LNM is controversial. The aim of this study was to clarify the efficacy of

131

I on LNM with good iodine uptake and the influencing factors.

Methods:

In this study

161 iodine positive metastasis lymph nodes from 90 DTC patients treated by

131

I from January 2015 to June 2019 in Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine were included

and the clinical and imaging data of the patients were analyzed. SPSS 24.0 software was used to make statistical analysis. The measurement data were distributed according to the normal distribution

then the independent sample

-test was compared. The comparison of

the counting data was conducted by

test

and the multivariate analysis was carried out by logistic regression analysis. The receiver operating characteristic (ROC) curve between multiple quantitative indexes and the failure of

131

I treatment were established

and the optimal diagnostic threshold was obtained.

Results:

Among 161 iodine positive metastasis lymph nodes

71 (44.10%) were effective

and 90 (55.90%) were ineffective. Univariate analysis showed that there were significant differences in age

gender

pathological type

number of primary lesions

location of primary lesions

distant metastasis and serum thyroglobulin (Tg) level between the two groups (

0.05). Multivariate logistic regression analysis showed that the pathological types (OR = 11.827

95% CI: 1.128-123.978

= 0.039)

distant metastasis (OR = 0.220

95% CI: 0.093-0.522

= 0.001) and number of primary lesions (OR = 0.421

95% CI: 0.212-0.837

= 0.014) were closely related to the outcome of the treatment.

Conclusion:

Multiple primary foci

papillary thyroid carcinoma (PTC)

distant metastasis

serum Tg higher than 43.51 ng/mL and the maximum diameter of metastatic lymph nodes greater than 16.8mm are the risk factors of ineffective

131

I treatment. Increasing the treatment dose or choosing surgical resection as soon as possible is recommended for those patients.

关键词

Keywords

references

LEE J Y , BAEK J H , HA E J , et al. 2020 imaging guidelines for thyroid nodules and differentiated thyroid cancer: Korean society of thyroid radiology [J ] . Korean J Radiol , 2021, 22 ( 5 ): 840 - 860 . DOI: 10.3348/kjr.2020.0578 http://doi.org/10.3348/kjr.2020.0578 https://kjronline.org/DOIx.php?id=10.3348/kjr.2020.0578 https://kjronline.org/DOIx.php?id=10.3348/kjr.2020.0578

HAUGEN B R , ALEXANDER E K , BIBLE K C , et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer [J ] . Thyroid , 2016, 26 ( 1 ): 1 - 133 . DOI: 10.1089/thy.2015.0020 http://doi.org/10.1089/thy.2015.0020 https://www.liebertpub.com/doi/10.1089/thy.2015.0020 https://www.liebertpub.com/doi/10.1089/thy.2015.0020

TAN L C , HUANG N S , YU P C , et al. Different clinicopathologic features predispose to different patterns of distant metastasis with heterogeneous short-term prognosis in patients with differentiated thyroid cancer [J ] . Clin Endocrinol (Oxf) , 2022 , 96 ( 3 ): 402 - 412 . DOI: 10.1111/cen.14602 http://doi.org/10.1111/cen.14602 https://onlinelibrary.wiley.com/doi/10.1111/cen.14602 https://onlinelibrary.wiley.com/doi/10.1111/cen.14602

GRØNLUND M P , JENSEN J S , HAHN C H , et al. Risk factors for recurrence of follicular thyroid cancer: a systematic review [J ] . Thyroid , 2021 , 31 ( 10 ): 1523 - 1530 . DOI: 10.1089/thy.2020.0921 http://doi.org/10.1089/thy.2020.0921

ILHAN H , MUSTAFA M , BARTENSTEIN P , et al. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study [J ] . Nuklearmedizin , 2016 , 55 ( 6 ): 221 - 227 .

CHUDGAR A V , SHAH J C . Pictorial review of false-positive results on radioiodine scintigrams of patients with differentiated thyroid cancer [J ] . Radiographics , 2017 , 37 ( 1 ): 298 - 315 . DOI: 10.1148/rg.2017160074 http://doi.org/10.1148/rg.2017160074

SCHMIDT D , LINKE R , UDER M , et al. Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation [J ] . Eur J Nucl Med Mol Imaging , 2010 , 37 ( 4 ): 699 - 705 . DOI: 10.1007/s00259-009-1299-2 http://doi.org/10.1007/s00259-009-1299-2 http://link.springer.com/10.1007/s00259-009-1299-2 http://link.springer.com/10.1007/s00259-009-1299-2

KIM H , KIM Y N , KIM H I , et al. Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer [J ] . Sci Rep , 2017 , 7 ( 1 ): 16955 . DOI: 10.1038/s41598-017-17176-6 http://doi.org/10.1038/s41598-017-17176-6

LI S , REN C T , GONG Y , et al. The role of thyroglobulin in preoperative and postoperative evaluation of patients with differentiated thyroid cancer [J ] . Front Endocrinol (Lausanne) , 2022 , 13 : 872527 . DOI: 10.3389/fendo.2022.872527 http://doi.org/10.3389/fendo.2022.872527 https://www.frontiersin.org/articles/10.3389/fendo.2022.872527/full https://www.frontiersin.org/articles/10.3389/fendo.2022.872527/full

郭彦君 , 王叙馥 , 王国强 , 等 . 分化型甲状腺癌术后 131 I清灶疗效及影响因素分析 [J ] . 中华核医学与分子影像杂志 , 2017 , 37 ( 11 ): 705 - 709 .

GUO Y J , WANG X F , WANG G Q , et al. Efficacy and influential factors of post-resection 131 I therapy on metastases from differentiated thyroid carcinoma [J ] . Chin J Nucl Med Mol Imaging , 2017 , 37 ( 11 ): 705 - 709 .

REN L , ZHANG C L , SHEN Y , et al. The value of stimulated thyroglobulin before the first radioactive iodine treatment in metastasis for differentiated thyroid carcinoma [J ] . Clin Lab , 2021 , 67 ( 6 ).

HAN Y , HOU L , ZHAO B W , et al. Risk factors for neck nodal metastasis in papillary thyroid cancer with BRAF V600E mutation [J ] . Front Endocrinol (Lausanne) , 2022 , 13 : 884428 . DOI: 10.3389/fendo.2022.884428 http://doi.org/10.3389/fendo.2022.884428 https://www.frontiersin.org/articles/10.3389/fendo.2022.884428/full https://www.frontiersin.org/articles/10.3389/fendo.2022.884428/full

WEI X J , WANG X D , XIONG J , et al. Risk and prognostic factors for BRAF V600E mutations in papillary thyroid carcinoma [J ] . Biomed Res Int , 2022 , 2022 : 9959649 .

RASHID F A , MUNKHDELGER J , FUKUOKA J , et al. Prevalence of BRAF V600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review [J ] . Gland Surg , 2020 , 9 ( 5 ): 1878 - 1900 . DOI: 10.21037/gs-20-430 http://doi.org/10.21037/gs-20-430 http://gs.amegroups.com/article/view/49445/html http://gs.amegroups.com/article/view/49445/html

SCHOULTZ E , JOHANSSON E , MOCCIA C , et al. Tissue architecture delineates field cancerization in BRAF V600E-induced tumor development [J ] . Dis Model Mech , 2022 , 15 ( 2 ): dmm048887 . DOI: 10.1242/dmm.048887 http://doi.org/10.1242/dmm.048887 https://journals.biologists.com/dmm/article/15/2/dmm048887/271800/Tissue-architecture-delineates-field-cancerization https://journals.biologists.com/dmm/article/15/2/dmm048887/271800/Tissue-architecture-delineates-field-cancerization

CAZARIN J , DUPUY C , PIRES DE CARVALHO D . Redox homeostasis in thyroid cancer: implications in Na + /I-symporter (NIS) regulation [J ] . Int J Mol Sci , 2022 , 23 ( 11 ): 6129 . DOI: 10.3390/ijms23116129 http://doi.org/10.3390/ijms23116129 https://www.mdpi.com/1422-0067/23/11/6129 https://www.mdpi.com/1422-0067/23/11/6129

DI GIUSTO P , MARTÍN M , et al. FUNES CHABÁN M, Transcription factor CREB3L1 regulates the expression of the sodium/iodide symporter (NIS) in rat thyroid follicular cells [J ] . Cells , 2022 , 11 ( 8 ): 1314 . DOI: 10.3390/cells11081314 http://doi.org/10.3390/cells11081314 https://www.mdpi.com/2073-4409/11/8/1314 https://www.mdpi.com/2073-4409/11/8/1314

KIM K J , KIM S G , TAN J , et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma [J ] . Eur J Cancer , 2020 , 124 : 161 - 169 . DOI: S0959-8049(19)30780-4 http://doi.org/S0959-8049(19)30780-4

WANG T T , SHI J Y , LI L C , et al. Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma [J ] . Front Immunol , 2022 , 13 : 840811 . DOI: 10.3389/fimmu.2022.840811 http://doi.org/10.3389/fimmu.2022.840811 https://www.frontiersin.org/articles/10.3389/fimmu.2022.840811/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.840811/full

卢承慧 , 李娇 , 刘新峰 , 等 . 首次 131 I治疗后淋巴结显影伴治疗前刺激性Tg阴性的分化型甲状腺癌的治疗反应及影响因素分析 [J ] . 中华核医学与分子影像杂志 , 2020 , 40 ( 1 ): 21 - 26 .

LU C H , LI J , LIU X F , et al. Treatment response of differentiated thyroid carcinoma with negative preablative stimulated thyroglobulin and iodine-positive lymph node after the first radioablation and influence factors analysis [J ] . Chin J Nucl Med Mol Imaging , 2020 , 40 ( 1 ): 21 - 26 .

浏览量

2871

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

时空转录组解析乳腺癌淋巴结转移与免疫调控相关性的进展及展望

《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：分化型甲状腺癌的外照射放疗进展

《2025版美国甲状腺学会成人甲状腺结节管理指南》及《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：甲状腺结节及分化型甲状腺癌超声、CT、MRI以及消融部分的进展

《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：围手术期甲状旁腺功能的评估、处理及术后TSH抑制的精准个体化管理

《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：分化型甲状腺癌的核医学诊治进展

摄碘阳性的分化型甲状腺癌淋巴结转移灶131I疗效分析

Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after 131I treatment

DOI：10.19401/j.cnki.1007-3639.2022.11.007

摘要

Abstract

关键词

Keywords

references

摄碘阳性的分化型甲状腺癌淋巴结转移灶¹³¹I疗效分析

Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after ¹³¹I treatment